EGFR and non-small cell lung carcinoma: According to our model findings, the results of our base case analysis suggest that osimertinib exhibits superior health outcomes but yields higher costs in comparison to placebo among individuals with stage IB to IIIA, EGFR-mutated, completely resected NSCLC.